Acquisition contributes iCAD's commercial, technology, and regulatory capabilities

收购增强了iCAD的商业、技术和监管能力

The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutions

该收购使DeepHealth拥有一套行业领先的、由人工智能驱动的乳腺癌图像解读和工作流程解决方案。

The combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies

该组合有望加速人工智能的采用，并扩大全球对先进乳腺癌筛查和诊断技术的访问。

LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in AI-powered breast health solutions.

洛杉矶，2025年7月17日（GLOBE NEWSWIRE）-- RadNet, Inc.（纳斯达克股票代码：RDNT）（“RadNet”），作为提供高质量、经济高效的诊断影像服务和数字健康解决方案的全国领导者，今天宣布已完成对iCAD, Inc.（纳斯达克股票代码：ICAD）（“iCAD”）的收购，后者是全球领先的AI驱动乳腺健康解决方案提供商。

The integration of iCAD's complementary commercial, technology, and regulatory capabilities into DeepHealth advances DeepHealth’s mission to address clinical and operational challenges in screening and diagnosis by harnessing the power of AI and imaging..

将iCAD互补的商业、技术和监管能力整合到DeepHealth中，推动了DeepHealth通过利用人工智能和成像技术的力量来解决筛查和诊断中的临床和运营挑战的使命。

Kees Wesdorp, President and CEO of RadNet’s Digital Health segment, commented, “We are excited to welcome the iCAD team to DeepHealth. The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs, while shaping the future of breast cancer management.

RadNet数字健康部门总裁兼首席执行官Kees Wesdorp表示：“我们非常高兴欢迎iCAD团队加入DeepHealth。iCAD的整合进一步增强了DeepHealth满足当今现实临床需求的能力，从提高乳腺癌诊断的准确性与早期检测，到组织大规模筛查项目，同时也在塑造乳腺癌管理的未来。”

Our combined capabilities position us for accelerated growth and rapid delivery of transformative, AI-powered population health solutions.”.

我们的综合能力使我们能够加速增长，并快速交付变革性的、由人工智能驱动的群体健康解决方案。”

iCAD’s extensive AI portfolio—including breast cancer detection, risk evaluation, breast density, and breast arterial calcification assessment—is deployed in more than 50 countries. This portfolio will be integrated with DeepHealth’s end-to-end screening and diagnostic solutions, further improving both cancer detection rates and workflow efficiency.

iCAD广泛的AI产品组合——包括乳腺癌检测、风险评估、乳腺密度和乳腺动脉钙化评估——已部署在50多个国家。该产品组合将与DeepHealth的端到端筛查和诊断解决方案集成，进一步提高癌症检测率和工作流程效率。

By uniting complementary technologies and datasets, the combined portfolio can further enhance AI model performance and enable the delivery of a comprehensive suite of AI-powered image interpretation and workflow solutions that address real-world clinical needs across the cancer screening and detection pathways..

通过整合互补的技术和数据集，合并后的组合可以进一步提升人工智能模型的性能，并实现一套全面的、由人工智能驱动的图像解读和工作流程解决方案，满足癌症筛查和检测路径中的实际临床需求。

With expanded market access through iCAD's installed base of over 1,500 healthcare provider locations worldwide, this strategic acquisition enables DeepHealth to scale its impact to over 10 million mammograms annually. This global reach aims to accelerate AI adoption and screening compliance by bringing advanced AI-powered solutions to communities around the world, including those that are underserved..

通过iCAD在全球范围内超过1500家医疗机构的庞大市场覆盖，此次战略性收购使DeepHealth能够将其影响力扩展到每年超过1000万次乳腺X光检查。这一全球覆盖旨在通过将先进的AI驱动解决方案带给世界各地的社区（包括服务不足的地区），加速人工智能的应用和筛查合规性。

About RadNet

关于RadNet

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas.

RadNet, Inc. 是美国领先的独立固定式诊断影像服务提供商，其领先地位基于所拥有的中心数量和年度影像收入。 RadNet 拥有并/或经营着一个由 401 个门诊影像中心组成的网络。 RadNet 的影像中心市场覆盖亚利桑那州、加利福尼亚州、特拉华州、佛罗里达州、马里兰州、新泽西州、纽约州和德克萨斯州。

In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees.

此外，RadNet 还提供以 DeepHealth 品牌销售的放射学信息技术和人工智能解决方案、远程放射学专业服务以及其他相关产品和服务给诊断成像行业的客户。连同签约的放射科医生，以及包括全职和按日计酬的员工和技术人员在内，RadNet 共有超过 11,000 名员工。

For more information, visit .

欲了解更多信息，请访问。

http://www.radnet.com

http://www.radnet.com

.

。

About DeepHealth

关于DeepHealth

DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health.

DeepHealth 是 RadNet, Inc.（纳斯达克股票代码：RDNT）的全资子公司，作为 RadNet 数字健康部门所有公司的统一品牌。DeepHealth 提供人工智能驱动的健康信息学，旨在通过影像技术推动护理领域的突破。DeepHealth 整合并重塑了旗下多家公司的品牌（例如，eRAD 放射信息与影像管理系统及影像存档和通信系统、Aidence 肺部 AI、DeepHealth、Kheiron 和 iCAD 乳腺 AI、Quantib 前列腺和脑部 AI，以及 See-Mode 甲状腺和乳腺 AI），利用先进的人工智能提升运营效率，并改善肺部、乳腺、前列腺和脑部健康的临床结果。

At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs.

DeepHealth 产品组合的核心是一个云原生操作系统——DeepHealth OS，它统一了临床和操作工作流程中的数据，并为放射学领域的每个人提供个性化的 AI 工作空间。全球数百家影像中心和放射科部门的数千名放射科医生使用 DeepHealth 解决方案，以实现更早、更可靠和更高效的疾病检测，包括在大规模癌症筛查项目中。

DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. .

DeepHealth以人为本、直观的技术旨在突破医疗保健领域的可能性界限。

https://deephealth.com/

https://deephealth.com/

RadNet Contact

RadNet 联系方式

Mark Stolper

马克·斯托尔珀

Executive Vice President and Chief Financial Officer

执行副总裁兼首席财务官

310-445-2800

310-445-2800

DeepHealth Contact

深健康联系

Andra Axente

安德拉·阿克森特

Director of Communications

通讯主任

+31614440971

+31614440971

andra.axente@deephealth.com

安德拉·阿克森特@深度健康.康姆

Forward-Looking Statements

前瞻性声明

This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods.

本通讯包含某些“前瞻性陈述”，这些陈述符合1995年《美国私人证券诉讼改革法案》、修订后的《1933年证券法》第27A条以及修订后的《1934年证券交易法》第21E条中的安全港条款。前瞻性陈述可以通过以下词语来识别：“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“打算”、“或许”、“展望”、“计划”、“潜在”、“可能”、“推测”、“预计”、“寻求”、“应该”、“目标”、“将”或“会”，以及这些词语的否定形式和对未来期间的类似提及。

Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change.

前瞻性陈述的示例包括关于收购预期收益的陈述、收购对RadNet业务及未来财务和运营结果与前景的影响，以及收购带来的协同效应的金额和时间，这些均基于RadNet当前的估计、假设和预测，并受限于围绕未来预期的一般性固有风险和不确定性，所有这些均可能发生变化。

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control..

由于存在许多风险和不确定性，实际结果可能与当前预期的结果存在重大差异，其中许多风险和不确定性是RadNet无法控制的。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

前瞻性声明既不是历史事实，也不是对未来业绩的保证。相反，它们仅基于管理层对 RadNet 业务未来、未来计划和战略、预测、预期事件和趋势、经济状况及其他未来条件的当前信念、期望和假设。

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors.

由于前瞻性陈述与未来相关，因此它们受到固有的不确定性、风险和难以预测的环境变化的影响，其中许多因素超出RadNet的控制范围。RadNet的实际结果和财务状况可能因各种因素而与前瞻性陈述中所述的内容存在重大差异。

None of RadNet, iCAD or any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet.

RadNet、iCAD 或其各自的董事、高级管理人员或顾问均不提供任何陈述、保证或担保，即任何前瞻性声明中所表达或暗示的事件将实际发生，或者如果其中任何事件确实发生，它们将对 RadNet 的业务、经营结果或财务状况产生何种影响。

Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, the ability of RadNet or iCAD to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (2) the ability of RadNet to achieve the synergies contemplated by the acquisition or such synergie.

如果任何风险和不确定性发展为实际事件，这些发展可能对RadNet的业务以及实现收购预期收益的能力产生重大不利影响。可能导致结果与预期不同的风险和不确定性包括但不限于：(1) 实现收购预期收益的能力，这可能受到RadNet或iCAD能否维持与其客户、患者、支付方、医生及供应商的关系，并保留其管理层和关键员工的影响；(2) RadNet实现收购预期协同效应的能力，或此类协同效应的实现情况。

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent.

本文件中包含的前瞻性陈述仅截至本文件发布之日作出，除非适用法律要求，RadNet不承担更新任何前瞻性陈述或本通讯中的任何其他信息的义务，无论是否因新信息、未来发展或其他原因，也不对其中出现的任何不准确或遗漏进行更正。

All forward-looking statements in this communication are qualified in their entirety by this cautionary statement..

本通讯中所有的前瞻性陈述均受此警示性声明的全面限制。